trative data with limited adjustments, have found that the use of IVC filters was associated with reduced mortality rates, recommending their use. 5 This study sought to determine the association between use of IVC filters and mortality rates in Medicare FFS beneficiaries with PE using 3 distinct statistical approaches.
Methods | This study was exempt from additional review by the Human Investigation Committee at Yale University because all data were deidentified. Using the Medicare inpatient claims data and International Classification of Diseases, Ninth Revision, Clinical Modification codes, we identified elderly patients (aged ≥65 years) with a principal discharge diagnosis of PE (codes 415.1X, 415.11, 415.13, and 415.19 ) from 2011 to 2014. Procedure code 38.7 was used to identify patients who received an IVC filter. The main outcomes were 30-day and 1-year all-cause mortality rates. Mixed models were fitted with hospital as random effects, adjusting for patient characteristics (Table) .
To account for the potential imbalances in baseline characteristics, a weighted analysis with the stabilized inverse probability weighting (IPW) approach was used. Each patient was weighted by inverse propensity scores of receiving an IVC filter, and the model only included the IVC filter use indicator (yes or no). To obtain the propensity scores, a logistic regression model was fitted with receiving an IVC filter as a dependent variable and baseline characteristics as covariates. The score performance was evaluated by comparing the standardized mean proportion difference in patient characteristics between the IVC filter group and no IVC filter group after the IPW adjustment. A difference of 0.2 or more was considered a significant imbalance.
In addition, a matched cohort was created for patients with PE who received an IVC filter and for those who did not. We matched for each of the individual characteristics exactly (ie, same demographics and same comorbidities) and compared the mortality rates. Analyses were performed using SAS, version 9.4 (SAS Institute).
Results | There were 214 579 FFS beneficiaries (57.4% women; 84.9% white; mean [SD] age, 77.8 [7.9] years) hospitalized for acute PE, of whom 13.4% received an IVC filter. Those receiving an IVC filter had a higher 30-day mortality rate than those who did not receive a filter (11.6% vs 9.3%). The adjusted odds ratio (OR) of 30-day mortality was 1.02 (95% CI, 0.98-1.06). The findings from the IPW analysis were statistically significant (OR, 1.16; 95% CI, 1.12-1.21).
One-year mortality rates among patients who survived longer than 30 days after index admission ware 20.5% in the IVC filter group and 13.4% in the no IVC filter group. In the model adjusted for patient characteristics, the adjusted OR was 1.35 (95% CI, 1.31-1.40), and in the model with IPW, the adjusted OR was 1.56 (95% CI, 1.52-1.61). Among patient characteristics used for risk adjustment, the maximum absolute IPWadjusted standardized mean difference was 0.04, indicating that there were no substantial imbalances.
In the individually matched cohort, 76 198 FFS beneficiaries were hospitalized with acute PE, of whom 18.2% received an IVC filter. Mixed models with IVC filter as the dependent variable showed that the IVC filter group had higher odds for 30-day mortality (OR, 1.61; 95% CI, 1.50-1.73) and 1-year mortality (OR, 2.19; 95% CI, 2.06-2.33) compared with the no filter group (Figure) . Discussion | Our study of Medicare FFS beneficiaries with acute PE, consistent across 3 different statistical adjustment methods, does not suggest an association between IVC filter use and lower mortality rates. These findings stand in contrast with prior reports from administrative databases that suggested efficacy of IVC filters but did limited adjustment for potential confounders.
5 Instead, our study showed hypothesisgenerating findings for increased risk.
The limitations of this study should be noted. First, limitations of administrative claims bring uncertainty for claiming the efficacy of health interventions using such data. 6 Second, the IPW analysis may become unstable in case the estimated propensities are small. However, in this study, the large size of the study cohort minimized this concern. Third, immortal time bias is another factor to consider in controlled studies in which an exposure (treatment) occurs only in 1 group. Patients in the exposure group need to be alive (immortal) until the day of the procedure, which may suggest a false beneficial treatment effect. In this analyses, however, patients receiving IVC filters did not have reduced mortality rates and the study did not adjust for immortal time bias. Despite the limitations, these findings in combination with the paucity of evidence from trials raise concerns about the widespread use of these IVC filters.
There is a need for more and better studies (randomized clinical trials or prospective controlled observational stud- 
